MEMarion Eveillard

Marion Eveillard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marion Eveillard has a total of 230 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characterization of a Novel SREBF1::CIC Transcript in a Neonatal Soft Tissue Sarcoma

    by Emma Gendron, Baptiste Le Calvez, Gaelle Pierron, Mathilde Filsez, Louise Galmiche‐Rolland, Marion Eveillard, Thomas Lefrançois, Morgane Cleirec, Audrey Grain

  • Deep Learning‐Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening

    by Cédric De Almeida Braga, Maxence Bauvais, Pierre Sujobert, Maël Heiblig, Maxime Jullien, Baptiste Le Calvez, Camille Richard, Valentin Le Roc'H, Emmanuelle Rault, Olivier Hérault, et al.

    Introduction: VEXAS is a syndrome described in 2020, caused by mutations of the UBA1 gene, and displaying a large pleomorphic array of clinical and hematological features. Nevertheless, these criteria lack significance to discriminate VEXAS from other inflammatory conditions at the screening step. This work hence first focused on singling out dysplastic features indicative of the syndrome among peripheral blood (PB) polymorphonuclears (PMN). A deep learning algorithm is then proposed for automatic detection of these features.Methods: A multicentric dataset, comprising 9514 annotated PMN images was gathered, including UBA1 mutated VEXAS (n = 25), UBA1 wildtype myelodysplastic (n = 14), and UBA1 wildtype cytopenic patients (n = 25). Statistical analysis on a subset of patients was performed to screen for significant abnormalities. Detection of these features on PB was then automated with a convolutional neural network (CNN) for multilabel classification.Results: Significant differences were observed in the proportions of PMNs with pseudo‐Pelger, nuclear spikes, vacuoles, and hypogranularity between patients with VEXAS and both cytopenic and myelodysplastic controls.Automatic detection of these abnormalities yielded AUCs in the range [0.85–0.97] and a F1‐score of 0.70 on the test set. A VEXAS screening score was proposed, leveraging the model outputs and predicting the UBA1 mutational status with 0.82 sensitivity and 0.71 specificity on the test patients.Conclusion: This study suggests that computer‐assisted analysis of PB smears, focusing on suspected VEXAS cases, can provide valuable insights for determining which patients should undergo molecular testing. The presented deep learning approach can help hematologists direct their suspicions before initiating further analyses.


  • Open Access

    Purplish granules as a cytological signature of cortical developmental disorders caused by pathogenic variants in WDR81

    by Baptiste Le Calvez, Thomas Besnard, Benjamin Cogne, Stéphane Bézieau, Marie C. Béné, Claire Beneteau, Marion Eveillard


  • Neonatal diagnosis of congenital dyserythropoietic anemia type II

    by Apolline Lelard, Baptiste Le Calvez, Simon Bouzy, Marie Laure Couec, Marion Eveillard

  • Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide

    by Maxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, Pierre Peterlin, Alice Garnier, Marion Eveillard, Yannick Le Bris, Simon Bouzy, Benoît Tessoulin, Thomas Gastinne, et al.

    The presence of donor Vγ9Vδ2 T‐cells after haploidentical hematopoietic stem cell transplant (h‐HSCT) has been associated with improved disease‐free survival. These cells kill tumor cells in a non‐MHC restricted manner, do not induce graft‐versus‐host disease (GVHD), and can be generated by stimulation with zoledronic acid (ZA) in combination with interleukin‐2 (IL‐2). This monocentric phase I, open‐label, dose‐escalating study (ClinicalTrials.gov: NCT03862833) aimed at evaluating the safety and possibility to generate Vγ9Vδ2 T‐cells early after h‐HSCT. It applied a standard 3 + 3 protocol to determine the maximum tolerated dose (MTD) of increasing low‐doses of IL‐2 (5 days [d] per week, 4 weeks) in combination with a single dose of ZA, starting both the first Monday after d + 15 posttransplant. Vγ9Vδ2 T‐cell monitoring was performed by multiparameter flow cytometry on blood samples and compared with a control cohort of h‐HSCT recipients. Twenty‐six patients were included between April 2019 and September 2022, 16 of whom being ultimately treated and seven being controls who received h‐HSCT only. At the three dose levels tested, 1, 0, and 1 dose‐limiting toxicities were observed. MTD was not reached. A significantly higher number of Vγ9Vδ2 T‐cells was observed during IL‐2 treatment compared with controls. In conclusion, early in vivo generation of Vγ9Vδ2 T‐cells is feasible after h‐HSCT by using a combination of ZA and repeated IL‐2 infusions. This study paves the way to a future phase 2 study, with the hope to document lesser posttransplant relapse with this particular adaptive immunotherapy.


  • Open Access

    Assessment of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients

    by Pierre Peterlin, Marie C. Béné, Maxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, Alice Garnier, Camille Debord, Marion Eveillard, Patrice Chevallier

    In this monocentric prospective study, the influence on long‐term outcomes of peripheral blood levels of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) was investigated in 56 patients with acute leukemia (myeloid n = 47; lymphoid n = 9) before and after (Days+60/+90) allogeneic hematopoietic stem cell transplantation (Allo‐HSCT). A risk of relapse was found to be associated with a level of pregraft M‐MDSC above 1.4% by ROC curve analysis. In multivariate analysis, this threshold retained a strong statistical significance (HR: 5.94 [2.09–16.87], p = 0.001). Considering only the group of patients who were in complete remission prior to Allo‐HSCT (n = 44), a significant prediction of relapse was found to be associated, in multivariate analysis, with a level of pregraft M‐MDSC above 1.4% (HR: 55.01 [14.95–202.37], p < 0.001) together with pregraft‐positive measurable ‐residual disease (MRD) (HR: 11.04 [1.89–64.67], p = 0.008). A poorer OS (HR: 6.05 [1.24–29.59], p = 0.026) and disease‐free survival (HR: 6.52 [1.41–30.19], p = 0.016) were also associated with higher levels of pregraft M‐MDSC. Remarkably, no relapse occurred in patients with pregraft‐negative MRD and ≤1.4% of M‐MDSC (vs. a 3‐year relapse rate of 60% for others, p = 0.004). Patients developing grade 3–4 acute graft‐versus‐host‐disease (GVHD, median occurrence: day+30 posttransplant) showed significantly higher levels of M‐MDSC% at days +60 and +90, suggesting a possible amplification of these immunosuppressive cells as a reaction to GVHD. In conclusion, this prospective study demonstrates a negative impact of higher proportions of peripheral M‐MDSC before Allo‐HSCT in leukemic patients. This paves the way to potential therapeutic intervention to decrease M‐MDSC levels before Allo‐HSCT and thus perhaps the incidence of relapse in such patients.


  • Open Access

    Bone marrow necrosis in childhood: The hunt for blasts

    by Baptiste Le Calvez, Margaux Camuset, Camille Debord, Audrey Grain, Marion Eveillard

  • Prothrombin consumption as an indicator of hemorrhagic phenotype in mild platelet function disorders

    by Antoine Babuty, Camille Debord, Nicolas Drillaud, Marion Eveillard, Marc Trossaert, Catherine Ternisien, Marianne Sigaud, Emmanuelle Cador, Marie C. Béné, Marc Fouassier

    Background: The bleeding risk of patients with mild platelet function disorders is difficult to assess and their phenotype remains ill‐explored.Aim: This study was designed to establish a comprehensive biological phenotype of patients with mild platelet function disorders.Methods: Twenty patients were included with persistent abnormal light transmission aggregometry (LTA). The ISTH bleeding assessment tool (ISTH‐BAT) was assessed to identify laboratory analyses associated with an abnormal hemorrhagic score.Results: The majority of patients had defects that might affect Gαi protein signaling pathways or minor abnormalities. No LTA nor flow cytometry parameters were associated with an above‐normal hemorrhagic score. However, prothrombin consumption, which corresponds to the ratio of serum residual factor II to plasma residual factor II, was significantly higher (p = .006) in the abnormal ISTH‐BAT group (mean = 14%, SD = 6) compared with the normal ISTH‐BAT group (mean = 8%, SD 4). Prothrombin consumption was significantly associated with ISTH‐BAT score (r = .5287, IC 95% 0.0986–0.7924, p = .0165).Conclusion: In this group of patients, there was an association between a pathological bleeding score and increased prothrombin consumption. This test could be used as an additional indicator of platelet function abnormality liable to be related to bleeding risk.


  • Open Access

    System-level immune monitoring reveals new pathophysiological features in hepatitis-associated aplastic anemia

    by Cecile Braudeau, Laurence Delbos, Marie-Laure Couec, Gwenvael Danic, Justine Chevreuil, Camille Lecuroux, Audrey Grain, Marion Eveillard, Fanny Rialland, Flore Sicre de Fontbrune, et al.

    Cecile Braudeau, Laurence Delbos, Marie-Laure Couec, Gwenvael Danic, Justine Chevreuil, Camille Lecuroux, Audrey Grain, Marion Eveillard, Fanny Rialland-Battist


  • Open Access

    Added value of molecular karyotype in childhood acute lymphoblastic leukemia

    by Margaux Camuset, Baptiste Le Calvez, Olivier Theisen, Catherine Godon, Audrey Grain, Caroline Thomas, Marie‐Laure Couec, Marie C. Béné, Fanny Rialland, Marion Eveillard

    Background: Thanks to an improved therapeutic regimen in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), 5 year‐overall survival now exceeds 90%. Unfortunately, the 25% of children who relapse have an initial poor prognosis, potentially driven by pre‐existing or emerging molecular anomalies. The latter are initially and essentially identified by cytogenetics. However, some subtle alterations are not visible through karyotyping.Methods: Single nucleotide polymorphisms (SNP) array is an alternative way of chromosomal analysis allowing for a more in‐depth evaluation of chromosomal modifications such as the assessment of copy number alterations (CNA) and loss of heterozygosity (LOH). This method was applied here in retrospective diagnosis/relapse paired samples from seven children with BCP‐ALL and in a prospective cohort of 38 newly diagnosed childhood cases.Results: In the matched study, compared to the initial karyotype, SNP array analysis reclassified two patients as poor prognosis cases. Modulation during relapse was seen for 4 CNA and 0.9 LOH. In the prospective study, SNP reclassified the 10 patients with intermediate karyotype as 7 good prognosis and 3 poor prognosis. Ultimately, in all the children tested, SNP array allowed to identify additional anomalies compared to conventional karyotype, refine its prognostic value and identify some druggable anomalies that could be used for precision medicine. Overall, the anomalies detected could be segregated in four groups respectively involved in B‐cell development, cell proliferation, transcription and molecular pathways.Conclusion: SNP therefore appears to be a method of choice in the integrated diagnosis of BCP ALL, especially for patients initially classified as intermediate prognosis. This complementary method of both cytogenetics and high throughput sequencing allows to obtain further classified information and can be useful in case of failure of these techniques.